has become the preferred management strategy for men with low risk prostate cancer. Despite widespread acceptance, many men that start AS will eventually progress and require treatment, though predicting this occurrence remains a challenging clinical dilemma. The objective of this study is to evaluate for clinical risk factors (RFs) that might aid in the risk stratification of these patients.
INTRODUCTION AND OBJECTIVES: Active surveillance (AS)
has become the preferred management strategy for men with low risk prostate cancer. Despite widespread acceptance, many men that start AS will eventually progress and require treatment, though predicting this occurrence remains a challenging clinical dilemma. The objective of this study is to evaluate for clinical risk factors (RFs) that might aid in the risk stratification of these patients.
METHODS: We performed a retrospective review of men on AS for low risk prostate cancer within the Northwell Health System. Records were queried for clinical RFs including PSA density (PSAD), total and free PSA, multiparametric MRI (mp-MRI) findings, and surveillance biopsy results. Univariate and multivariate Chi Square and Logistic Regression analyses were performed to test for associations between Gleason upgrade at last known follow up and clinical, laboratory, and imaging related RFs. Only patients meeting UCSF criteria for active surveillance at time of initial diagnosis were included in analyses (T1 or T2a, Gleason 6, less than 1/3 of total cores positive for cancer).
RESULTS: 336 men were identified as having pursued an AS strategy for some length of time. Of those, 212/336 (63.1%) had had a total and free PSA, a mp-MRI, and had undergone at least 1 surveillance biopsy. 61 of 212 (28.8%) had Gleason upgrade at the time of last known surveillance biopsy. On univariate analyses, the following variables were statistically significant predictors of Gleason upgrade (Table 1) : initial PSAD, initial PSAD <0.10, initial %freePSA, initial PIRADS score, negative intervening biopsy, PSAD increase of at least 0.05. On multivariate analysis of PSAD, % Free PSA, and PIRADS score, initial PSAD remained a statistically significant predictor of Gleason upgrade (p [ 0.032).
CONCLUSIONS: There are several clinical, laboratory, and imaging related risk factors that seem able to predict Gleason upgrade in patients on AS. Of these factors, PSAD, particularly at a cutoff of 0.1ng/ml/cc, was an independent predictor of upgrade. Given the abundance of risk factors clinicians can better counsel patients as to their suitability for remaining on AS or choosing earlier therapy.
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PD55-12 INCREMENTAL UTILITY OF MP-MRI PERFORMED BEFORE CONFIRMATORY BIOPSY IN REDUCING THE RISK OF PROGRESSION DURING ACTIVE SURVEILLANCE FOR MEN WITH LOW RISK PROSTATE CANCER: IS IMAGING ALWAYS USEFUL?
Marco Bandini, Luigi Nocera*, Simone Scarcella, Nazareno Suardi, Giorgio Gandaglia, Nicola Fossati, Armando Stabile, Milan, Italy; Shahrokh Shariat, Vienna, Austria; Pierre Karakiewicz, Montreal, Canada; Paolo Dell'Oglio, Milan, Italy; Nicola Longo, Vincenzo Mirone, Naples, Italy; Simone Scuderi, Daniele Robesti, Aldo Rizzo, Donato Cannoletta, Francesco Barletta, Antony Pellegrino, Francesco Montorsi, Alberto Briganti, Milan, Italy INTRODUCTION AND OBJECTIVES: The strongest evidence in favor of the use of mp-MRI in active surveillance (AS) for low risk prostate cancer (PCa) is prior to confirmatory biopsy. However, whether all patients benefit from mp-MRI in this setting is currently unknown. Indeed, it is possible that in very low-risk PCa patients the risk of missing clinically significant PCa is so low that the added value of subsequent imaging is minimal. We hypothesized that the clinical utility of mp-MRI before confirmatory biopsy to predict AS progression depends significantly on PCa features METHODS: Between 2007-18, we enrolled in our AS program patients with low risk PCa (PSA<10ng/ml, cT stage T2a and Gleason Score 6). Mp-MRI was suggested to patients after the enrollment of AS, before confirmatory biopsy. Multivariable Cox regression model (Age, cT stage, baseline PSA, % of positive cores and prostate volume) predicting progression (Gleason !3þ4) was developed for patients who did not underwent MRI. C-index quantified the discrimination accuracy of our model. We then tested the interaction between the use of MRI and the probability of progression according to the newly developed model. The nonparametric curve fitting method graphically explored the relationship between the risk of progression and actual progression rate RESULTS: We enrolled 235 patients. Overall, MRI was performed in 139 (60%) patients. Within a median follow-up of 25.2 months, 92 (39%) patients had progression. The C-index of our model was 84%. The interaction between the use of MRI and the risk of progression was statistically significant (p[0.04). The nonparametric curve fitting method showed that the use of MRI was associated with reduced risk of progression only for those patients with predicted probabilities >30% (Fig) CONCLUSIONS: Our results suggest that the utility of mp-MRI before confirmatory biopsy in men on AS vary significantly according to patient profile. In patients with very low risk PCa, according to our model, the added value of mp-MRI in reducing the risk of progression or misclassification is minimal. Thus, mp-MRI can be safely spared in these men. Only patients with a baseline probability of progression >30% might benefit from mp-MRI in order to exclude clinically significant PCa . We sought to analyze the oncological outcomes of men undergoing primary RPLND at our institution over the last decade to better characterize the use of template dissections and adjuvant chemotherapy.
METHODS: A retrospective review of the Indiana University testis cancer database identified patients who underwent open RPLND for NSGCT from 01/2007 to 12/2017. Patients and referring providers were contacted to obtain information regarding receipt of adjuvant therapy, recurrence and vital status. Those who could not be contacted were excluded. Recurrence rates were compared between numerous demographic and clinical variables. Kaplan-Meier curves were constructed to assess differences in recurrence-free survival (RFS) between pathological stage and use of adjuvant chemotherapy use. Differences between the curves were assessed using the logrank test.
RESULTS: Recurrence and survival data was obtained for 87% of identified patients. After exclusion criteria, 268 patients were included in the study. The median age at presentation was 28 INTRODUCTION AND OBJECTIVES: Presence of teratoma in the orchiectomy and residual retroperitoneal (RP) mass size are known predictors of teratoma in retroperitoneum at the time of postchemotherapy retroperitoneal lymph node dissection (PC-RPLND). We sought to determine if the percentage of teratoma in the orchiectomy specimen could better stratify the risk of teratoma in the retroperitoneum.
METHODS: A retrospective review of the Indiana University testis cancer database was performed to identify all patients who underwent PC-RPLND for non-seminomatous germ cell tumors from January 2010 to April 2018. Men with primary retroperitoneal tumors and without documented histologic composition of the orchiectomy were excluded. Teratoma in the orchiectomy was categorized into: none, 1-33%, 34-66%, 67-99% and pure teratoma. A logistic
